n-n-dimethylsphingenine and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

n-n-dimethylsphingenine has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for n-n-dimethylsphingenine and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine. Leukemia research, 2002, Volume: 26, Issue:3 We evaluated the cytotoxicity of dimethylsphingosine (DMS) against four human leukemia cell lines: two acute (HL60 and a multi-drug resistance MDR-positive derivative HL60-dox) and two blast crisis chronic myelogenous leukemias (JFP1, from a treatment refractory patient and K562), and against blasts isolated from 11 leukemia patients. Cell line viability decreased proportionally to DMS concentration and treatment time (P<0.001). HL60-dox and JFP1 were the most sensitive, indicating DMS efficacy against human leukemia MDR. Importantly, leukemia samples showed a similar sensitivity to DMS as that of the cell lines, firstly demonstrating PKC-independent sphingolipid activity against fresh human tumor specimens. DMS-based chemotherapy may improve leukemia treatment. Topics: Antineoplastic Agents; Blast Crisis; Bone Marrow Cells; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Sphingosine; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002

Article

Year

Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine.

Leukemia research, 2002, Volume: 26, Issue:3

We evaluated the cytotoxicity of dimethylsphingosine (DMS) against four human leukemia cell lines: two acute (HL60 and a multi-drug resistance MDR-positive derivative HL60-dox) and two blast crisis chronic myelogenous leukemias (JFP1, from a treatment refractory patient and K562), and against blasts isolated from 11 leukemia patients. Cell line viability decreased proportionally to DMS concentration and treatment time (P<0.001). HL60-dox and JFP1 were the most sensitive, indicating DMS efficacy against human leukemia MDR. Importantly, leukemia samples showed a similar sensitivity to DMS as that of the cell lines, firstly demonstrating PKC-independent sphingolipid activity against fresh human tumor specimens. DMS-based chemotherapy may improve leukemia treatment.

Topics: Antineoplastic Agents; Blast Crisis; Bone Marrow Cells; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Sphingosine; Tumor Cells, Cultured; Tumor Stem Cell Assay

2002